Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Gotratix5 residuesAEDRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: A-18, Gotratix A-18, Gotratix bioregulator
Thirty-seven people. That's the entire human evidence base for Gotratix, a Khavinson-class oral peptide bioregulator extracted from young bovine muscle tissue. The St. Petersburg Institute of Bioregulation and Gerontology ran one internal study on sport veterans aged 40 to 65, and it showed improved physical performance scores at 30 days. No peer-reviewed trial has followed. Gotratix sits in the broader Khavinson bioregulator framework, which spans four decades of published research on tissue-specific short peptides. Longevity and biohacking communities use it in 30-day oral courses for muscle recovery, typically stacked alongside Epithalon or Cartalax.
Thirty-seven sport veterans in St. Petersburg. That's the sum total of published human data on Gotratix (designation A-18), a muscle-targeted peptide bioregulator from the Khavinson class. The compound contains short-chain peptides (2 to 7 amino acid residues, molecular weight below 10 kDa) extracted from young calf striated muscle tissue through acid hydrolysis and ultrafiltration. The proposed mechanism is gene-level. These tissue-derived peptides are thought to cross myocyte cell membranes, enter the nucleus, and bind specific DNA sequences in gene promoter regions. That binding is claimed to normalize protein synthesis, restore cellular metabolism, and increase functional reserve capacity in muscle tissue. Related Khavinson peptides have been shown to modulate histone acetylation and DNA methylation in vitro [1]. In practice, Gotratix is an oral capsule product. Each capsule contains 200 mg of polypeptide complex. Standard protocols call for 1 to 2 capsules daily for 30 days, repeated every 4 to 6 months. No injection or reconstitution is required. The single human study (St. Petersburg Institute, April to November 2011, n=37, ages 40 to 65) tracked step-test performance and dorsal spine mobility. Both improved vs controls. But the study is unindexed, not peer-reviewed internationally, and didn't specify the dose used. Community evidence is similarly thin: fewer than 10 English-language anecdotal reports and 5 verified buyer reviews on rupharma.com. Most discussion happens in Russian. The broader Khavinson bioregulator research program spans 40+ years and includes published work on Cortexin, Epithalon, and other tissue-specific peptides [2]. That body of work supports the general concept of short-peptide gene regulation. Gotratix itself has yet to produce the kind of dedicated clinical data that would move it beyond theoretical.
Gotratix operates within the Khavinson bioregulator framework. The muscle-derived short peptides in this product are proposed to act as epigenetic modulators of gene expression, specific to their tissue of origin. The mechanism starts with absorption. These small peptides (2 to 7 amino acids) survive gastric digestion due to their size. Once absorbed through intestinal epithelium, they circulate to muscle tissue. The proposed next step is entry into myocyte nuclei, where they interact with specific nucleotide sequences in gene promoter regions. Khavinson's group has demonstrated this DNA-peptide interaction in vitro for related short peptides [1]. The binding affects histone acetylation and DNA methylation patterns, changing which genes are accessible for transcription. For muscle tissue, the claimed downstream effects include upregulation of structural proteins like myosin and actin, restoration of metabolic enzyme activity, and normalization of the balance between protein synthesis and degradation. Mitochondrial function in muscle cells may also be affected. Supporting energy production during contraction is part of the manufacturer's proposed benefit set. The honest assessment: these mechanisms are extrapolated from the broader Khavinson research platform. No Gotratix-specific mechanistic study has been published. The in vitro evidence on related peptides is real; the leap to Gotratix-specific myocyte gene regulation in living humans hasn't been validated.
No PubMed-indexed Gotratix-specific trials. One unindexed internal study (St. Petersburg Institute, 2011, n=37 sport veterans 40–65) showed improved step-test performance and dorsal spine mobility vs controls. Broader Khavinson bioregulator research (published, indexed) supports tissue-specific short-peptide gene regulation but does not directly validate Gotratix's muscle claims.
Internal institute report, St. Petersburg Institute of Bioregulation and Gerontology, Apr–Nov 2011 (n=37, NOT indexed in PubMed)
Only one human study, unindexed and not peer-reviewed in international journals. No placebo-controlled RCT. Dose not specified in available report. Outcome measures limited to physical performance tests. No long-term follow-up data.
Extremely limited English-language community. Positive anecdotal reviews on rupharma.com (5 stars, 5 verified buyers). Most community discussion is in Russian. Biohacking/longevity community treats it as part of multi-bioregulator stacking protocols rather than a standalone compound.
Both the single human study and community reports suggest modest muscle recovery and performance benefits consistent with the bioregulator mechanism, but the evidence base is too thin on both sides to call this truly aligned. Community use reflects the manufacturer's intended population (40+ adults with sarcopenia/recovery goals) and dosing is consistent with the internal study protocol.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mg | Daily |
| Moderate | 400mg | Daily |
| Aggressive | 400mg | 2x Daily |
Gotratix is an oral capsule, so there's no reconstitution math to worry about. Each capsule contains 200 mg of polypeptide complex. You swallow it whole with water, 15 to 20 minutes before a meal. That timing matters for absorption. Standard starting dose is 1 capsule (200 mg) daily for 30 days. Some practitioners use a loading protocol: 2 capsules twice daily (800 mg/day) for 10 days, then 1 to 2 capsules daily for the remaining 20 days. Don't exceed 4 capsules (800 mg) in a single day. The thing most beginners miss with bioregulators: you won't feel anything dramatic. These aren't stimulants. Track your workout recovery scores and performance metrics before and after the course. Without a baseline, you'll never know if Gotratix did anything. Courses repeat every 4 to 6 months. The Khavinson model claims gene expression changes persist for months post-course, so continuous daily dosing is unnecessary and just burns money. Store capsules at room temperature (15 to 25 degrees C), away from moisture and direct sunlight.
Standard protocol: 1-2 capsules, 1-2 times daily for 30 days. Repeat every 4-6 months. An intensive loading phase of 2 capsules twice daily for 10 days followed by standard dosing for 20 days is used by some practitioners. Take 15-20 minutes before meals for best absorption.
Khavinson bioregulators are cycled based on the proposed epigenetic mechanism: tissue-derived short peptides are believed to initiate lasting gene expression changes that persist 3–6 months post-course without continued supplementation. Continuous daily dosing is unnecessary per the model and adds cost without additional benefit. The 30-day course / 4–6 month break structure is designed to align supplementation with the natural decline of the residual gene expression effect.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced muscle soreness by weeks 2–3; modest improvement in recovery time between sessions by end of course. Effects may persist 3–6 months post-course per bioregulator model.
Monitor: No bloodwork required. Track subjective recovery scores and workout performance metrics before and after the course to assess response.
Take 1 capsule (200 mg) by mouth, 15 to 20 minutes before a meal. Swallow whole with water. Do not open or crush the capsule.
For the standard course, take 1 capsule once daily for 30 days. That's 30 capsules total, or half of a 60-capsule pack.
For the moderate protocol, take 2 capsules (400 mg) once daily for 30 days. This doubles the daily dose and uses one full 60-capsule pack.
For the intensive loading protocol (experienced users only), take 2 capsules (400 mg) twice daily for 10 days, then reduce to 1 to 2 capsules once or twice daily for 20 days. Maximum daily dose is 4 capsules (800 mg). Do not exceed this.
If training around the dose, take capsules 30 to 45 minutes before a workout and again before the post-workout meal.
Store unopened capsules at 15 to 25 degrees C, protected from moisture and direct sunlight. Shelf life is up to 2 years in original sealed packaging.
After completing the 30-day course, wait 4 to 6 months before repeating. Athletes in heavy training blocks sometimes repeat at 3 months.
200 mg per capsule; 1–4 caps/day (200–800 mg)
Take 15–20 minutes before meals. Swallow whole with water. Available in 20-cap and 60-cap packs.
Sublingual may improve bioavailability for intact peptide fragments: no comparative dosing data exists
Bypasses first-pass gut metabolism. Theoretically superior for peptide fragment delivery if mechanism requires intact peptides to reach myocytes via circulation. Higher cost than capsule form. No head-to-head comparison study.
Complementary tissue targeting: Gotratix targets myocytes while Cartalax targets cartilage. Commonly stacked for connective tissue + muscle recovery protocols in the longevity/biohacking community.
Standard Khavinson longevity stack: Epithalon provides pineal/anti-aging bioregulation while Gotratix handles muscle support. Combined as a multi-bioregulator course.
Combining Gotratix oral bioregulator with injectable BPC-157 for injury recovery. Reported on Longecity forums for musculoskeletal injury cases (e.g., tendon/muscle injuries).
Often added alongside BPC-157 in a healing stack. Gotratix provides the oral bioregulator component; TB-500 adds systemic tissue repair signaling.
Theoretical interaction: peptide bioactivity may interfere with immunosuppressive drug mechanisms. No formal interaction data exists. Consult prescribing physician.
Combining an epigenetic muscle bioregulator with a myostatin inhibitor introduces unpredictable additive effects on muscle protein synthesis. Both are poorly characterized in humans: combined use multiplies unknowns. Not studied together.
No safety data on combining Gotratix gene-regulatory mechanism with IGF-1 anabolic signaling. Both affect myocyte protein synthesis through different pathways: interaction unknown.
Pricing updated 2026-04-09
The biggest concern with Gotratix isn't a specific adverse event. It's the absence of safety data. No formal pharmacovigilance program has tracked this compound. No clinical trial has systematically collected adverse event reports. The side effect profile is based on a handful of user reviews and the general safety record of the Khavinson bioregulator class. Bovine protein hypersensitivity is the most concrete risk. Gotratix is extracted from young calf muscle tissue. Anyone with known sensitivity to bovine-derived proteins should avoid this product entirely. Allergic reactions (hives, respiratory symptoms, gastrointestinal distress) are theoretically possible, though documented cases across the broader bioregulator class are rare. Gastrointestinal discomfort is the most commonly reported complaint. Bloating and mild nausea occur occasionally, particularly at the 2-capsule dose taken on an empty stomach. Adjusting timing to 15 to 20 minutes before meals typically resolves this. If symptoms persist, reducing to 1 capsule per serving is the standard recommendation. The autoimmune question deserves attention. Gotratix contains animal-derived peptide fragments that interact with gene expression per the proposed mechanism. For individuals with active autoimmune conditions affecting muscle tissue (myositis), introducing exogenous peptides that modulate myocyte gene transcription is an unknown risk. This is listed as a contraindication by the manufacturer. No drug interaction studies have been published. Theoretical concerns exist around immunosuppressive medications, since the peptide bioactivity could interfere with immunosuppression. Combining Gotratix with other muscle-active peptides (follistatin, IGF-1 LR3) introduces unpredictable additive effects on protein synthesis pathways. Pregnancy and breastfeeding: no safety data exists. Not recommended. Children under 18 have not been studied. The bottom line on tolerability: the Khavinson bioregulator class has a decades-long track record without major safety signals. But "no major signals" from a product with minimal Western-market surveillance is different from "proven safe." Anyone starting Gotratix should watch for allergic reactions in the first week and report persistent GI symptoms to a healthcare provider.
Verify Gotratix dosing and safety with a second opinion
Gotratix is produced by Peptide Bioregulator Ltd (Russia) and distributed through CIS-market suppliers. The manufacturing process (acid hydrolysis + ultrafiltration of bovine tissue) is documented at the institutional level, but there is no third-party GMP certification visible to Western buyers. Rupharma is the most commonly cited Western-market supplier with a track record in Khavinson products, but independent purity testing data for this specific compound is not publicly available. The risk is medium rather than high because the Khavinson institute has a 40+ year manufacturing history with established bioregulators like Epithalon and Cortexin.
| Test | When | Target |
|---|---|---|
| Subjective recovery score | Before starting course, at day 15, and at day 30 | — |
| Workout performance log | Weekly throughout 30-day course | — |
| Allergy symptom check | First 7 days | — |
No objective blood test exists for Gotratix bioactivity. Tracking workout recovery (soreness scale, next-day fatigue) is the only practical way to assess response.
The internal study measured step-test performance as primary outcome. Tracking similar endurance/strength metrics allows comparison to baseline.
Bovine-derived peptide complex: rare but possible hypersensitivity reaction in first week of use.
No noticeable effects expected. The bioregulator peptides are beginning to interact with muscle cell gene expression pathways according to the proposed mechanism.
Some users anecdotally report reduced muscle fatigue and improved recovery between workouts, though placebo effects can't be ruled out given the lack of controlled trials.
Proposed peak period of the treatment course. Claimed improvements in muscle endurance, reduced soreness after physical activity, and better overall muscle tone.
Effects are said to persist after the course ends due to lasting gene expression changes. This claim is based on the broader bioregulator model rather than Gotratix-specific data.
Repeated courses are recommended for cumulative benefit. The manufacturer suggests that ongoing peptide supplementation maintains optimal myocyte peptide balance over time.
Days 1 to 7: Nothing noticeable. The peptide fragments are absorbing and beginning to interact with myocyte gene promoter regions per the Khavinson model. No measurable physiological change happens this early. Community reports are unanimous on this; first-week expectations should be zero. Occasional mild GI adjustment is possible but rare, and typically resolves within 3 to 4 days. Days 8 to 14: Early, subtle signals start appearing for some users. If the gene expression modulation mechanism is operative, altered transcription of muscle repair genes would be underway at this point. Some users report reduced muscle soreness after workouts and slightly better next-day energy. These improvements are described as subtle rather than dramatic. Placebo effect can't be excluded given the lack of controlled data. Days 15 to 30: This is the proposed peak window. The manufacturer's model predicts full bioregulator effect on myocyte protein synthesis and metabolic normalization within this period. The single internal study measured its outcomes at the 30-day mark. Most anecdotal benefits cluster here: better muscle endurance, reduced soreness, improved workout capacity. Some users report improved muscle appearance and fullness. Weeks 5 to 12 (post-course): The Khavinson model predicts that gene expression changes persist 3 to 6 months after the course ends, without continued supplementation. No Gotratix-specific data supports this claim. A handful of users note gradual decline in recovery benefits by weeks 8 to 10. Most transition to repeat-course scheduling around month 4 to 6. 4 to 6 months (repeat course): The standard repeat window. Longevity community members commonly run 2 courses per year as maintenance. Athletes may push to 2 or 3 courses per year during heavy training periods. The manufacturer frames repeated courses as maintaining optimal myocyte peptide balance over time.
Peptide fragments absorbing, beginning to interact with myocyte gene promoter regions per Khavinson model. No measurable physiological change expected this early.
Universally reports no effects in the first week. Some users question whether capsules are working.
Gene expression modulation beginning: if the mechanism is operative, altered transcription of muscle repair genes would be underway. No direct evidence for this timeline.
Some users report reduced muscle soreness after workouts and slightly improved next-day energy. Described as subtle: not dramatic. Placebo effect cannot be excluded.
Manufacturer's proposed window for full bioregulator effect on myocyte protein synthesis and metabolic normalization. The internal study measured outcomes at 30 days.
Most anecdotal benefits cluster here: better muscle endurance, reduced soreness, improved workout capacity. Some report improved muscle appearance/fullness.
Khavinson model predicts lasting gene expression changes persist 3–6 months post-course without continued supplementation. No Gotratix-specific data for this claim.
A handful of users note gradual decline in recovery benefits by weeks 8–10 post-course. Most switch to repeat-course scheduling at month 4–6.
Repeated courses designed to maintain optimal myocyte peptide balance: per manufacturer protocol.
Longevity users in the Khavinson community commonly run 2 courses per year as a maintenance regimen. Athletes may run 2–3 courses per year during high-training periods.
Source: Estimated from short peptide complex kinetics; no Gotratix-specific pharmacokinetic studies published (extrapolated from Khavinson bioregulator class)
Loading the interactive decay curve.
Gotratix is classified as research-only outside of Russia and CIS countries. It does not have FDA approval, EMA authorization, or TGA listing. In Russia, it is marketed as a dietary supplement under the Khavinson bioregulator product line by Peptide Bioregulator Ltd. No regulatory applications for Gotratix have been filed with Western health authorities. The compound is available from specialty suppliers including Rupharma, Firma-vita, Cosmic Nootropic, and Longevity Research Products. These are not compounding pharmacies; they are importers of the Russian-manufactured product. WADA status: Gotratix is not specifically listed on the WADA prohibited list. However, athletes subject to anti-doping testing should verify current status with their governing body, as peptide bioregulators occupy a gray area in competitive sport regulations. This content is for informational purposes only and does not constitute medical advice. Gotratix has not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Consult a qualified healthcare provider before starting any peptide protocol.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
